18 A phase 2, open-label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab
- Resource Type
- Abstract
- Source
- In
Immunobiology September 2023 228(5) - Subject
- Language
- ISSN
- 0171-2985